Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. (Q53902292)

22 May 2018

title

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. (English)

1 reference

22 May 2018

obsessive-compulsive disorder

1 reference

1 reference

F Bogetto

1

1 reference

22 May 2018

S Bellino

series ordinal

2

1 reference

22 May 2018

P Vaschetto

series ordinal

3

1 reference

22 May 2018

S Ziero

series ordinal

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 October 2000

1 reference

22 May 2018

published in

Psychiatry Research

1 reference

22 May 2018

volume

96

1 reference

22 May 2018

issue

2

1 reference

22 May 2018

page(s)

91-98

1 reference

22 May 2018

Effect of Axis II Diagnoses on Treatment Outcome With Clomipramine in 55 Patients With Obsessive-Compulsive Disorder

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Exacerbation of obsessive-compulsive symptoms associated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Is there a relationship between clozapine and obsessive-compulsive disorder?: a retrospective chart review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

The Yale-Brown Obsessive Compulsive Scale. II. Validity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

1 reference

7 January 2021

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Concomitant obsessive-compulsive disorder and schizotypal personality disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Special feature: pharmacotherapy in personality disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

A family history study of schizophrenia-related personality disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Long-term follow-up of 85 patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Development of transient obsessive-compulsive symptoms during treatment with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Biologic factors in schizotypal personal disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Changes in daily mood and self-restraint among undercontrolled preadolescents: a time-series analysis of "acting out".

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900203-1

7 January 2021

10.1016/S0165-1781(00)00203-1

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

11063782

1 reference

22 May 2018